AbbVie Inc. (ABBV) said the European Medicines Agency’s Committee for
Medicinal Products for Human Use adopted a positive opinion for Rinvoq
for the treatment of adult patients with moderate to severe active
rheumatoid arthritis.
The CHMP positive opinion is supported by data from the pivotal Phase
3 SELECT rheumatoid arthritis program evaluating more than 4,400
patients, AbbVie said. The opinion will now be referred to the European
Commission for final approval, the company said.
In Phase 3 trials, upadacitinib improved signs and symptoms of
rheumatoid arthritis, inhibited radiographic progression and improved
physical function, AbbVie said.
https://www.marketscreener.com/ABBVIE-12136589/news/AbbVie-Gets-CHMP-Positive-Opinion-for-Rinvoq-in-Rheumatoid-Arthritis-29416286/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.